These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17906456)

  • 1. Individualized pharmacotherapy with paclitaxel.
    Mielke S
    Curr Opin Oncol; 2007 Nov; 19(6):586-9. PubMed ID: 17906456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel.
    Henningsson A; Marsh S; Loos WJ; Karlsson MO; Garsa A; Mross K; Mielke S; Viganò L; Locatelli A; Verweij J; Sparreboom A; McLeod HL
    Clin Cancer Res; 2005 Nov; 11(22):8097-104. PubMed ID: 16299241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity.
    Leskelä S; Jara C; Leandro-García LJ; Martínez A; García-Donas J; Hernando S; Hurtado A; Vicario JC; Montero-Conde C; Landa I; López-Jiménez E; Cascón A; Milne RL; Robledo M; Rodríguez-Antona C
    Pharmacogenomics J; 2011 Apr; 11(2):121-9. PubMed ID: 20212519
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacogenetic studies of Paclitaxel in the treatment of ovarian cancer.
    Gréen H; Söderkvist P; Rosenberg P; Mirghani RA; Rymark P; Lundqvist EA; Peterson C
    Basic Clin Pharmacol Toxicol; 2009 Feb; 104(2):130-7. PubMed ID: 19143748
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacogenetic screening of CYP3A and ABCB1 in relation to population pharmacokinetics of docetaxel.
    Bosch TM; Huitema AD; Doodeman VD; Jansen R; Witteveen E; Smit WM; Jansen RL; van Herpen CM; Soesan M; Beijnen JH; Schellens JH
    Clin Cancer Res; 2006 Oct; 12(19):5786-93. PubMed ID: 17020985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. P-glycoprotein and cytochrome P450 3A act together in restricting the oral bioavailability of paclitaxel.
    Hendrikx JJ; Lagas JS; Rosing H; Schellens JH; Beijnen JH; Schinkel AH
    Int J Cancer; 2013 May; 132(10):2439-47. PubMed ID: 23090875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Influence of Cremophor EL and genetic polymorphisms on the pharmacokinetics of paclitaxel and its metabolites using a mechanism-based model.
    Fransson MN; Gréen H; Litton JE; Friberg LE
    Drug Metab Dispos; 2011 Feb; 39(2):247-55. PubMed ID: 21056987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetic variation in ABCB1 influences paclitaxel pharmacokinetics in Japanese patients with ovarian cancer.
    Yamaguchi H; Hishinuma T; Endo N; Tsukamoto H; Kishikawa Y; Sato M; Murai Y; Hiratsuka M; Ito K; Okamura C; Yaegashi N; Suzuki N; Tomioka Y; Goto J
    Int J Gynecol Cancer; 2006; 16(3):979-85. PubMed ID: 16803472
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics and pharmacogenetics of vincristine in paediatric patients treated for solid tumour diseases.
    Guilhaumou R; Simon N; Quaranta S; Verschuur A; Lacarelle B; Andre N; Solas C
    Cancer Chemother Pharmacol; 2011 Nov; 68(5):1191-8. PubMed ID: 21404110
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine markedly raises the plasma concentrations of repaglinide.
    Kajosaari LI; Niemi M; Neuvonen M; Laitila J; Neuvonen PJ; Backman JT
    Clin Pharmacol Ther; 2005 Oct; 78(4):388-99. PubMed ID: 16198658
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective study of the impact of pharmacogenetic variants on paclitaxel toxicity and survival in patients with ovarian cancer.
    Bergmann TK; Gréen H; Brasch-Andersen C; Mirza MR; Herrstedt J; Hølund B; du Bois A; Damkier P; Vach W; Brosen K; Peterson C
    Eur J Clin Pharmacol; 2011 Jul; 67(7):693-700. PubMed ID: 21327421
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population.
    Bosch TM; Doodeman VD; Smits PH; Meijerman I; Schellens JH; Beijnen JH
    Mol Diagn Ther; 2006; 10(3):175-85. PubMed ID: 16771603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Association of ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia.
    Sissung TM; Mross K; Steinberg SM; Behringer D; Figg WD; Sparreboom A; Mielke S
    Eur J Cancer; 2006 Nov; 42(17):2893-6. PubMed ID: 16950614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacogenetics of taxanes: impact of gene polymorphisms of drug transporters on pharmacokinetics and toxicity.
    Jabir RS; Naidu R; Annuar MA; Ho GF; Munisamy M; Stanslas J
    Pharmacogenomics; 2012 Dec; 13(16):1979-88. PubMed ID: 23215890
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and toxicity of docetaxel: role of CYP3A, MDR1, and GST polymorphisms.
    Tran A; Jullien V; Alexandre J; Rey E; Rabillon F; Girre V; Dieras V; Pons G; Goldwasser F; Tréluyer JM
    Clin Pharmacol Ther; 2006 Jun; 79(6):570-80. PubMed ID: 16765145
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Threshold for antiproliferative and proapoptotic activity of ttaxol in HepG2 cells expressing human CYP3A4: effect of P-glycoprotein transporters.
    Holownia A; Cederbaum AI
    Pharmacology; 2003 Nov; 69(3):142-9. PubMed ID: 14512701
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic polymorphisms and paclitaxel- or docetaxel-induced toxicities: A systematic review.
    Frederiks CN; Lam SW; Guchelaar HJ; Boven E
    Cancer Treat Rev; 2015 Dec; 41(10):935-50. PubMed ID: 26585358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics.
    Niemi M; Backman JT; Kajosaari LI; Leathart JB; Neuvonen M; Daly AK; Eichelbaum M; Kivistö KT; Neuvonen PJ
    Clin Pharmacol Ther; 2005 Jun; 77(6):468-78. PubMed ID: 15961978
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia.
    Yamakawa Y; Hamada A; Nakashima R; Yuki M; Hirayama C; Kawaguchi T; Saito H
    Ther Drug Monit; 2011 Apr; 33(2):244-50. PubMed ID: 21311410
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacogenomics of celiprolol - evidence for a role of P-glycoprotein and organic anion transporting polypeptide 1A2 in celiprolol pharmacokinetics.
    Hirvensalo P; Tornio A; Tapaninen T; Paile-Hyvärinen M; Neuvonen M; Backman JT; Niemi M
    Clin Transl Sci; 2022 Feb; 15(2):409-421. PubMed ID: 34585840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.